Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 28, 2018
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S J Luen, R Salgado, M V Dieci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, W F Symmans, J Stec, et al.
Breast Cancer Research : BCR
|
June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Roberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, W F Symmans, et al.
Endocrine-Related Cancer
|
December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
W F Symmans, D J Fiterman, S K Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2013
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
F Bertucci, N T Ueno, P Finetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 28, 2018
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S J Luen, R Salgado, M V Dieci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, W F Symmans, J Stec, et al.
Breast Cancer Research : BCR
|
June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Roberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, W F Symmans, et al.
Endocrine-Related Cancer
|
December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
W F Symmans, D J Fiterman, S K Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2013
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
F Bertucci, N T Ueno, P Finetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Page
of 6